Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421459 · ClinicalTrials.gov registry record · Phase 3
A Study in Adults With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 759
- Enrollment target
NCT01421459: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT01421459 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 759 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01421459, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 759 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
Primary Outcome
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.
Interventions
- DRUG LY2963016
- DRUG Lantus
- DRUG OAMs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 759 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
What the finished NCT01421459 record still lists
NCT01421459 is an interventional study that assigns participants to a tested intervention. The registered 759 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which LY2963016 is the first listed.
NCT01421459 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01421459 about?
NCT01421459 is a clinical study titled "A Study in Adults With Type 2 Diabetes". The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
What is the current status of trial NCT01421459?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 759 participants. The study started on 2011-09. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01421459?
The interventions under investigation include: LY2963016 (DRUG), Lantus (DRUG), OAMs (DRUG).
Who is sponsoring clinical trial NCT01421459?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01421459's enrollment target sits among peer trials
759 455th of 2000 higher than 1,545 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02089607 · 760 participants · NA
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
- NCT04073706 · 760 participants · Phase 3
Sentinel Node Biopsy in Endometrial Cancer
- NCT05129228 · 760 participants · NA
Optical Coherence Tomography of the Saphenous Vein Graft
- NCT05787821 · 760 participants
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia